Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.940999
Keywords
total saikosaponins; Alzheimer's disease; A beta; p-tau; Nrf2; autophagy; gut microbiota
Categories
Funding
- National Natural Science Foundation of China [82160759, 82060792, 81660645, 81660673]
- Key R&D Program of Ningxia [2018BFG02005, 2021BEG03100]
- Natural Science Foundation of Ningxia [2020AAC03133, 2021AAC03143]
- Fourth Batch of Ningxia Youth Talents Supporting Program [TJGC2019091, TJGC2019100]
Ask authors/readers for more resources
This study found that total saikosaponins (TS) could ameliorate cognitive dysfunction in Alzheimer's disease (AD) by activating nuclear factor 2 (Nrf2) and downregulating the expression of beta-secretase 1 (BACE1), reducing the generation of amyloid-beta (A beta) and senile plaque deposition. TS also enhanced autophagy, inhibited the activation of nuclear factor-kappa B (NF-kappa B), and improved synaptic loss and oxidative stress.
Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory loss and cognitive dysfunction in the elderly, with amyloid-beta (A beta) deposition and hyperphosphorylation of tau protein as the main pathological feature. Nuclear factor 2 (Nrf2) is a transcription factor that primarily exists in the cytosol of hippocampal neurons, and it is considered as an important regulator of autophagy, oxidative stress, and inflammation. Total saikosaponins (TS) is the main bioactive component of Radix bupleuri (Chaihu). In this study, it was found that TS could ameliorate cognitive dysfunction in APP/PS1 transgenic mice and reduce A beta generation and senile plaque deposition via activating Nrf2 and downregulating the expression of beta-secretase 1 (BACE1). In addition, TS can enhance autophagy by promoting the expression of Beclin-1 and LC3-II, increasing the degradation of p62 and NDP52 and the clearance of phosphorylated tau (p-tau), and reducing the expression of p-tau. It can also downregulate the expression of nuclear factor-kappa B (NF-kappa B) to inhibit the activation of glial cells and reduce the release of inflammatory factors. In vitro experiments using PC12 cells induced by A beta, TS could significantly inhibit the aggregation of A beta and reduce cytotoxicity. It was found that Nrf2 knock-out weakened the inhibitory effect of TS on BACE1 and NF-kappa B transcription in PC12 cells. Moreover, the inhibitory effect of TS on BACE1 transcription was achieved by promoting the binding of Nrf2 and the promoter of BACE1 ARE1. Results showed that TS downregulated the expression of BACE1 and NF-kappa B through Nrf2, thereby reducing the generation of A beta and inhibiting neuroinflammation. Furthermore, TS can ameliorate synaptic loss and alleviate oxidative stress. In gut microbiota analysis, dysbiosis was demonstrated in APP/PS1 transgenic mice, indicating a potential link between gut microbiota and AD. Furthermore, TS treatment reverses the gut microbiota disorder in APP/PS1 mice, suggesting a therapeutic strategy by remodeling the gut microbe. Collectively, these data shows that TS may serve as a potential approach for AD treatment. Further investigation is needed to clarify the detailed mechanisms underlying TS regulating gut microbiota and oxidative stress.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available